作 者:冯雨晨 吴琼来 源:投资界(ID:pedaily2012)又一笔标志性医药并购诞生。本周,港股上市公司中国生物制药公告,将以不超9.51亿美元(约68.22亿元人民币)的对价收购礼新医药95.09%股权,扣除礼新医药账上约4.5亿美元现金后,净付款约5.01亿美元,创下2025年国内创新药领域最大并购纪录。卖方礼新医药,2019年由上海交大女博士秦莹创立,身后站着启明创投、泰格医药、博远...
Source Link作 者:冯雨晨 吴琼来 源:投资界(ID:pedaily2012)又一笔标志性医药并购诞生。本周,港股上市公司中国生物制药公告,将以不超9.51亿美元(约68.22亿元人民币)的对价收购礼新医药95.09%股权,扣除礼新医药账上约4.5亿美元现金后,净付款约5.01亿美元,创下2025年国内创新药领域最大并购纪录。卖方礼新医药,2019年由上海交大女博士秦莹创立,身后站着启明创投、泰格医药、博远...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.